Jaguar Health Inc (JAGX) Stock Price, Quote & News

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infe...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 371 8300

Website: jaguar.health

Address:

200 Pine Street, Suite 400, San Francisco, United States

andycoolbeans Mar. 20 at 8:05 PM

$JAGX when you see green at the end of the week

0 · Reply

Bunster Mar. 20 at 6:58 PM

$JAGX look for the real proxy filing today in an hour giving some color to the pre one filed last friday ah.

0 · Reply

andycoolbeans Mar. 20 at 6:16 PM

$JAGX I didn’t really think I was going to post today , but left a very sarcastic and snarky VM for them to listen to and someone replied to me . I sent them a response email expressing my hope they had a plan that attracted shareholders not screwed them over Dear Andrew, Thank you for reaching out. I hope all is well with you, and apologies for the delayed reply! The company expects to file it’s 10-K for 2025 by the required deadline, which falls on March 31, but the company has not yet announced the filing date. All the best, Peter Peter Hodge Vice President, Investor Relations, Business Development & Special Events Jaguar Health, Inc. mailto:[email protected] Headquarters: 200 Pine Street, Suite 400 San Francisco, CA 94104 http://www.jaguar.health

1 · Reply

Ms_Scammy121 Mar. 20 at 5:32 PM

$JAGX omggggg i can not wait!!!! I dont really trade much anymore focus on my real estate but i wouldnt miss this last rs for the world!

0 · Reply

MarketManStockWizzard Mar. 20 at 4:09 PM

$JAGX 1 for 22,500 reverse split after they use all 500,000,000 authorized shares. They are looking at guniess book of world records!

0 · Reply

MarketManStockWizzard Mar. 20 at 4:07 PM

$JAGX crazy as heckfire!

0 · Reply

The_Gambl3r Mar. 20 at 2:57 PM

$JAGX Spidey Senses

0 · Reply

MarketManStockWizzard Mar. 20 at 2:41 PM

$JAGX

0 · Reply

SmartestMoney Mar. 20 at 1:55 PM

$JAGX Negative 90%

0 · Reply

profitingstocks Mar. 20 at 11:19 AM

$JAGX New all time low, can we see .3’s before the weekend?

0 · Reply

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

Mar 16, 2026, 9:00 AM EDT - 5 days ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Mar 11, 2026, 9:00 AM EDT - 10 days ago

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Mar 9, 2026, 9:00 AM EDT - 12 days ago

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Mar 3, 2026, 9:00 AM EST - 17 days ago

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

Mar 2, 2026, 9:00 AM EST - 18 days ago

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

Feb 18, 2026, 9:00 AM EST - 4 weeks ago

Jaguar Health Announces a Special One-time Stock Dividend

Jan 22, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jan 14, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jan 12, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Jan 6, 2026, 9:00 AM EST - 2 months ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jan 2, 2026, 9:00 AM EST - 2 months ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 15, 2025, 9:00 AM EST - 3 months ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Dec 10, 2025, 9:00 AM EST - 3 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 8, 2025, 4:15 PM EST - 3 months ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Dec 2, 2025, 9:00 AM EST - 3 months ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Nov 24, 2025, 9:00 AM EST - 4 months ago

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

Nov 20, 2025, 9:00 AM EST - 4 months ago

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Nov 17, 2025, 8:00 AM EST - 4 months ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Nov 14, 2025, 9:00 AM EST - 4 months ago

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Nov 13, 2025, 9:00 AM EST - 4 months ago

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

Nov 6, 2025, 9:00 AM EST - 4 months ago

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Oct 24, 2025, 4:15 PM EDT - 5 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 6, 2025, 9:00 AM EDT - 5 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

Sep 30, 2025, 9:00 AM EDT - 6 months ago

FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease

Sep 25, 2025, 9:00 AM EDT - 6 months ago

Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Sep 24, 2025, 9:00 AM EDT - 6 months ago

Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition

Sep 23, 2025, 9:00 AM EDT - 6 months ago

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts

Sep 5, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

Aug 21, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs

Aug 19, 2025, 4:15 PM EDT - 7 months ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders

Aug 19, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)

Aug 14, 2025, 8:00 AM EDT - 7 months ago

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

Aug 12, 2025, 9:00 AM EDT - 7 months ago

Jaguar Health to Hold Investor Webcast Thursday, August 14 at 8:30 AM Eastern Regarding Q2 2025 Financials & Corporate Updates

Jul 10, 2025, 8:30 AM EDT - 9 months ago

Enrollment Initiated in Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jul 8, 2025, 9:00 AM EDT - 9 months ago

Coca Access and Benefit Sharing Agreement Authorized by Peru's National Institute of Agrarian Innovation (INIA) Supports Research Efforts of Jaguar Health and Filament Health Joint Venture, Magdalena Biosciences, into Potential Mental Health and CNS Indications of Coca

Jun 30, 2025, 9:00 AM EDT - 9 months ago

Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient

Jun 26, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Board of Directors Authorizes Company to Include Cryptocurrency as a Treasury Reserve Asset

Jun 25, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health to Pursue Approval of Canalevia in European Union for Treatment of General Diarrhea in Dogs

Jun 24, 2025, 4:15 PM EDT - 9 months ago

Jaguar Health Announces Extension of the Maturity Date of its Convertible Promissory Notes from Recently Closed Bridge Financing to January 30, 2026

Jun 23, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Provides Updates on Orphan Disease Intestinal Failure Development Program for Crofelemer

Jun 17, 2025, 9:00 AM EDT - 9 months ago

Jaguar Health Presenting June 18 at Emerging Growth Conference to Provide Updates on Near-Term Catalysts

Jun 11, 2025, 10:00 AM EDT - 10 months ago

First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs

Jun 9, 2025, 4:15 PM EDT - 10 months ago

REMINDER: Jaguar Health to Conduct Fireside Chat 9AM ET June 10 as Part of Lytham Partners' Spring 2025 Spotlight Series

Jun 9, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health Provides Update on Meeting with FDA Discussing Statistically Significant Results of Responder Analysis of Breast Cancer Patients in Phase 3 OnTarget Trial and Potential Approval Pathway for Crofelemer

Jun 6, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health to Conduct Fireside Chat June 10 Regarding Company's Efforts to Further its Orphan Disease Development Programs as Part of Lytham Partners' Spring 2025 Spotlight Series

May 21, 2025, 8:00 AM EDT - 10 months ago

Jaguar Health Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

May 20, 2025, 9:15 AM EDT - 10 months ago

First Patient Randomized in Jaguar Health's Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Crofelemer in Pediatric Patients with Microvillus Inclusion Disease (MVID)

May 15, 2025, 2:30 PM EDT - 11 months ago

Jaguar Health Reports First Quarter 2025 Financials

May 14, 2025, 9:00 AM EDT - 11 months ago

Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates

andycoolbeans Mar. 20 at 8:05 PM

$JAGX when you see green at the end of the week

0 · Reply

Bunster Mar. 20 at 6:58 PM

$JAGX look for the real proxy filing today in an hour giving some color to the pre one filed last friday ah.

0 · Reply

andycoolbeans Mar. 20 at 6:16 PM

1 · Reply

Ms_Scammy121 Mar. 20 at 5:32 PM

$JAGX omggggg i can not wait!!!! I dont really trade much anymore focus on my real estate but i wouldnt miss this last rs for the world!

0 · Reply

MarketManStockWizzard Mar. 20 at 4:09 PM

$JAGX 1 for 22,500 reverse split after they use all 500,000,000 authorized shares. They are looking at guniess book of world records!

0 · Reply

MarketManStockWizzard Mar. 20 at 4:07 PM

$JAGX crazy as heckfire!

0 · Reply

The_Gambl3r Mar. 20 at 2:57 PM

$JAGX Spidey Senses

0 · Reply

MarketManStockWizzard Mar. 20 at 2:41 PM

$JAGX

0 · Reply

SmartestMoney Mar. 20 at 1:55 PM

$JAGX Negative 90%

0 · Reply

profitingstocks Mar. 20 at 11:19 AM

$JAGX New all time low, can we see .3’s before the weekend?

0 · Reply

MarketManStockWizzard Mar. 20 at 8:37 AM

$JAGX this is where it gets dicey. Only 200 shares in total on the bid. If you are selling more than that, it could go to $0.00. be careful.

0 · Reply

MarketManStockWizzard Mar. 20 at 7:27 AM

$JAGX

0 · Reply

Omago78 Mar. 19 at 7:40 PM

$JAGX Just a reminder on the brilliance of this companies leadership, if you invested a mere $652,000,000 dollars in 2016 you would have a massive jagx portfolio value of $0.41...AND they are currently gearing up for RS number 6 in the last 7 years. I will be taking tomorrow off from posting, so I guess @andycoolbeans can try and pump this garbage without pushback.

1 · Reply

Duskfall Mar. 19 at 6:51 PM

$JAGX Took some today..

0 · Reply

Golferhack12 Mar. 19 at 6:37 PM

$JAGX today the stock hit another all-time low the stock has never been this low with the reverse split coming which I predict and so does the market we're going to drop easily another 50%

1 · Reply

jeni1988 Mar. 19 at 5:28 PM

$JAGX No matter bro, this stock dead 5 years ago

1 · Reply

MarketManStockWizzard Mar. 19 at 4:33 PM

$JAGX earnings suprise expected as jagx sold rights to mytesi. But the real knee jerker is they now no longer receive money on sales. Both for canalevia and mytesi. Spending stays the same as they are still responsible for manufacturing and production for next 5 years. Also, we know they will need $8M to $12M per quarter just to keep the lights on. Nobody will be fooled on earnings day.

1 · Reply

Omago78 Mar. 19 at 4:28 PM

$JAGX do we see the 0.3's today or monday?

0 · Reply

czarfast1 Mar. 19 at 4:18 PM

$JAGX Imodium works differently, and there are plenty of medications for headaches, just like for diarrhea. When I read your stupid stuff, my head started hurting, I just hope I don't get diarrhea😁, stop with your comments already.

1 · Reply

andycoolbeans Mar. 19 at 4:09 PM

$JAGX when you call the number (415) 371-8300 they give you three options. You can forget about them ever calling you back. But if you press 4,5 or 6 they have other people they connect you with. #4 on target clinical trials whatever that means and #6 sales and marketing team for one of their pet products Canalevia-CA1 Kind of a weird system - almost like finding a hidden drain in the Mario games

0 · Reply

czarfast1 Mar. 19 at 2:51 PM

$JAGX

0 · Reply

Omago78 Mar. 19 at 2:14 PM

$JAGX There are 3 certainties in life. Death, Taxes, and JAGX losing investors money.

1 · Reply

Market Cap	1.66M
Revenue (ttm)	11.69M
Net Income (ttm)	-38.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-329.26%
Debt to Equity Ratio	1.75

Volume	335,000
Avg Vol	4,636,420
Day's Range	N/A - N/A
Shares Out	3.74M
Stochastic %K	10%
Beta	0.03
Analysts	Hold
Price Target	$16.00